Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.
Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to a new study from McGill University in Canada.
A new study finds that rising placebo responses may play a part in the increasingly high failure rate for clinical trials of drugs designed to control chronic pain caused by nerve damage.
RSS